Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Translational Medicine: Bridging pharmaceutical discovery and development with IT (Review Report)

Published by: Datamonitor

Published: Jun. 7, 2007 - 61 Pages


Table of Contents


DATAMONITOR VIEW
CATALYST
SUMMARY
METHODOLOGY
EXECUTIVE SUMMARY
Introduction
Translational Medicine - Drug Development Transformed? (Market Focus)
Enabling Translational Medicine with Business Intelligence (Technology Focus)
Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus)
US IT Spending on Business Intelligence to 2012 - Pharmaceutical Technology (Databook)
Europe IT Spending on Business Intelligence to 2012 - Pharmaceutical Technology (Databook)
TRANSLATIONAL MEDICINE: DRUG DEVELOPMENT TRANSFORMED? (MARKET FOCUS)
Summary
Translational medicine is real and fueled by patient-centered care
Defining translational medicine
The pharmaceutical industry mirrors healthcare trends
Existing business models are called into question, driving translational medicine
A deepening research & development crisis is driving the adoption of alternative business models
Demographic shifts will overburden existing health systems
Threat by low-cost generic drugs is changing the industry's focus towards high value products
Private and public industry initiatives indicate translational medicine is gaining momentum
Both cultural and technology barriers slow the progress of translational medicine
Translational medicine challenges the traditional culture of drug development
Translational medicine requires a level of technology infrastructure that transcends the lab
A lack of urgency by some companies will slow the overall adoption of translational medicine
Data analytics will catalyze translational medicine and connect it to patient-centered care
ACTIONS
Present technology for translational medicine as part of an existing and familiar solution
Position technology as a partner in drug discovery and development
Demystify cultural and technology challenges by educating end users early
ENABLING TRANSLATIONAL MEDICINE WITH BUSINESS INTELLIGENCE (TECHNOLOGY FOCUS)
Summary
Market pressures are driving pharmaceutical firms to embrace translational medicine
External forces are driving the adoption of translational medicine
Translational research requires BI technology components
Data integration is a key component of a data warehousing solution for R&D
Components of integration must support both spatial and temporal information
Data analytics tools must be built with domain expertise in order to derive knowledge from information
BI solutions must reflect domain expertise in the drug development process
Technology for translational medicine must support different types of end users
Four technology features add value to a BI solution for translational medicine
The pharmaceutical market requires usable technologies that empower users, without dictating a process
Technology must be flexible in scaling both up or down
In translational medicine, solutions need to integrate various data, software and hardware
Harvesting scientific knowledge within and across departments is a sign of a collaborative technology feature
ACTIONS
Align technology to R&D and clinical workflow challenges
Offer flexible solutions to fit the dynamic drug development process
Do not assume your end users are 'bi-lingual'
EVALUATING BUSINESS INTELLIGENCE OPPORTUNITIES IN THE PHARMACEUTICAL INDUSTRY (STRATEGY FOCUS)
Summary
Market factors are driving adoption of translational medicine and specifically BI solutions
External pressures are driving pharmaceutical companies to embrace translational research
Both cultural and technology barriers slow the progress of translational medicine
BI opportunities exist at several levels within the pharmaceutical market
Enterprise-class BI solutions have the power to evolve with an organization's changing business needs
BI spending by end-user group in Big Pharma and Biotech differs significantly
The industry requires vendors with high market readiness in translational medicine
Market sizing information is necessary but insufficient for identifying which sector to target
Vendors should consider four criteria when evaluating market opportunities
Market presence influences client perception about a BI solution and its vendor
Industry-specific solutions reflect domain expertise
A sales force with industry experience will resonate with pharmaceutical clients
Partnerships with niche vendors or academic medical centers (AMCs) build credibility
BI vendors with high market readiness will realize the most success in the pharmaceutical industry
A number of vendors have implemented successful strategies for BI in pharmaceuticals
Genstruct
Oracle
SAS
ACTIONS
BI solutions for Biotech and Big Pharma are not one size fits...both
Approach an attaractive opportunity through the market-readiness lens
Partner with innovators
US IT SPENDING ON BUSINESS INTELLIGENCE TO 2012 - PHARMACEUTICAL TECHNOLOGY (DATABOOK)
Introduction
Spending by the US and Europe pharmaceutical industry on BI to 2012
Spending by the US pharmaceutical industry on BI to 2012
Spending on BI solutions by US pharmaceutical sub-segments to 2012
Spending by US Big Pharma on BI solutions by technology to 2012
Spending by US Biotech on BI solutions by technology to 2012
Spending by Global Big Pharma on BI solutions by end-user group to 2012
Spending by Global Biotech on BI solutions by end-user group to 2012
EUROPE IT SPENDING ON BUSINESS INTELLIGENCE TO 2012 - PHARMACEUTICAL TECHNOLOGY (DATABOOK)
Introduction
Spending by the US and Europe pharmaceutical industry on BI to 2012
Spending by the Big Pharma in Europe on BI to 2012
Spending on BI solutions by US pharmaceutical sub-segments to 2012
Spending by US Big Pharma on BI solutions by technology to 2012
Spending by Global Big Pharma on BI solutions by end-user group to 2012
Spending by Global Biotech on BI solutions by end-user group to 2012
APPENDIX
Definitions
Abbreviations
External methodology
Further reading
Datamonitor Technology Consultancy
Ask the analyst
List of Tables
Table 1: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
Table 2: Spending by US pharmaceutical industry on BI solutions to 2012
Table 3: Spending on BI solutions by US pharmaceutical sub-segments to 2012
Table 4: Spending by US Big Pharma on BI solutions by technology
Table 5: Spending by US Big Pharma on BI solutions by technology
Table 6: Spending by Big Pharma on BI solutions by end-user group to 2012 (US & Europe)
Table 7: Spending by Biotech on BI solutions by end-user group to 2012 (US & Europe)
Table 8: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
Table 9: Spending by the Big Pharma in Europe on BI to 2012
Table 10: Spending on BI solutions by Big Pharma in the UK, France, Switzerland and Germany to 2012
Table 11: Spending by Big Pharma in Europe on BI solutions by technology
Table 12: Spending by Big Pharma on BI solutions by end-user group to 2012 (US & Europe)
Table 13: Spending by Biotech on BI solutions by end-user group to 2012 (US)
List of Figures
Figure 1: Translational medicine vs. traditional drug development
Figure 2: As healthcare moves towards patient-centered care, the pharmaceutical industry takes a parallel direction through translational medicine.
Figure 3: Despite increased spending on R&D, the pharmaceutical industry is facing a deep productivity crisis.
Figure 4: An aging population worldwide will put pressure on the pharmaceutical industry and overburden healthcare markets overall
Figure 5: Fiercely autonomous silos of R&D research and clinical development characterize most pharmaceutical companies
Figure 6: Technology must move towards the core of drug discovery and development
Figure 7: Technology aligned to translational medicine supports dynamic rather than linear models
Figure 8: Data integration includes ETL, data cleansing and refresh functions to support real-time exchange of diverse data
Figure 9: Data analytics with domain expertise enable decision support for translational research
Figure 10: Description of horizontal and vertical end-user titles
Figure 11: Technology feature components must align with different end users
Figure 12: The Big Pharma sector is the largest market opportunity in BI solutions ($ spent)
Figure 13: BI spending by technology (services vs. software) 2006-2012
Figure 14: Big Pharma will spend more on BI tools for clinical and sales & marketing application than Biotech
Figure 15: A framework for evaluating BI market opportunities in the pharmaceutical industry
Figure 16: Both horizontal and niche vendors offer valuable BI solutions for translational medicine
Figure 17: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
Figure 18: Spending by US pharmaceutical industry (Big Pharma & Biotech) on BI solutions to 2012
Figure 19: Spending on BI solutions by US pharmaceutical sub-segments to 2012
Figure 20: Spending by US Big Pharma on BI solutions by technology
Figure 21: Spending by US Biotech on BI solutions by technology
Figure 22: Spending by Big Pharma on BI solutions by end-user group to 2012
Figure 23: Spending by Biotech on BI solutions by end-user group to 2012
Figure 24: Spending by US and Europe pharmaceutical industry on BI solutions to 2012
Figure 25: Spending by the Big Pharma in Europe on BI to 2012
Figure 26: Spending on BI solutions by Big Pharma in the UK, France, Switzerland and Germany to 2012
Figure 27: Spending by Big Pharma in Europe on BI solutions by technology
Figure 28: Spending by Big Pharma on BI solutions by end-user group to 2012 (US & Europe)
Figure 29: Spending by Biotech on BI solutions by end-user group to 2012 (US)

Abstract

Introduction

This report consists of five sections: Market Focus, Technology Focus, Strategy Focus and two Databook sections, bringing together all of the documents that comprise Datamonitor's pharmaceutical technology research theme entitled "Translational Medicine: Bridging Discovery and Development with IT".

Scope

  • Translational Medicine - Drug Development Transformed? (Market Focus)
  • Enabling Translational Medicine with Business Intelligence (Technology Focus)
  • Evaluating Business Intelligence Opportunities in the Pharmaceutical Industry (Strategy Focus)
  • US and Europe IT Spending on Business Intelligence to 2012 (Databooks)


    • Highlights

    Existing business models are called into question, driving translational medicine

    Translational research requires BI technology components

    BI vendors with high market readiness will realize the most success in the pharmaceutical industry

    Reasons to Purchase

  • Gain valuable industry insight into the market drivers and inhibitors for translational medicine
  • Align your go-to-market strategy with both the organizational and technology needs of the pharmaceutical industry
  • Quantify the current and projected market opportunity for business intelligence tools in North American and European Big Pharma and Biotech


    • Get Full Details About This Report >>
    US: 800.298.5699
    Int'l: +1.240.747.3093
    Buy this Report
    Price and Delivery Options
    Search Inside Report


    advertise with us

     

    About MarketResearch.com
    MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

     

    © MarketResearch.com 2008